SCHEMBL15430341

SCHEMBL15430341

c1ccc(-c2cc(-c3ccccc3)c3oc4c(-c5cccc(-c6ccc7c(c6)c6ccccc6c6nccn76)c5)cc(-c5ccccc5)cc4c3c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 2/20 0.34
CDK2 P24941 2/20 0.34
TACR1 P25103 2/20 0.33
PRKDC P78527 5/20 0.33
PIK3CA P42336 1/20 0.32
PLA2G2A P14555 2/20 0.31
PLA2G4A P47712 2/20 0.31
PLA2G10 O15496 1/20 0.31
EED O75530 1/20 0.30
CHEK1 O14757 1/20 0.30
MAP4K4 O95819 1/20 0.30
CSF1R P07333 1/20 0.30
PRKACA P17612 1/20 0.30
KDR P35968 1/20 0.30
CDK8 P49336 1/20 0.30
MAP2K1 Q02750 1/20 0.30
ACVR1 Q04771 1/20 0.30
MAP4K2 Q12851 1/20 0.30
ROCK1 Q13464 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15430340 0.93 PLA2G2A (0.33) CCNE1CDK2TACR1PRKDCPLA2G2A
SCHEMBL15430338 0.91 PRKDC (0.36) CCNE1CDK2TACR1PRKDCPIK3CA
SCHEMBL15430264 0.85 CCNE1 (0.34) CCNE1CDK2TACR1PIK3CACHEK1
SCHEMBL15430337 0.85 PRKDC (0.32) PRKDC
SCHEMBL15430302 0.84 ALOX5 (0.43) PRKDCPLA2G2APLA2G4APLA2G10
SCHEMBL15430304 0.84 ALOX5 (0.46) PRKDCPLA2G2APLA2G4APLA2G10
SCHEMBL13309571 0.84 TACR1 (0.41) CCNE1CDK2TACR1PIK3CACHEK1
SCHEMBL15430345 0.83 PRKDC (0.36) TACR1PRKDCCDK8ROCK1
SCHEMBL15430298 0.83 ALOX5 (0.46) PRKDCPLA2G2APLA2G4APLA2G10
SCHEMBL15430305 0.83 ALOX5 (0.46) PRKDCPLA2G2APLA2G4APLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140014930-A1 Organic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2014-01-16 US disclosed
US-20140014930-A1 Organic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2014-01-16 US disclosed
US-20070037979-A1 Preparation of rosuvastatin TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037979-A1 Preparation of rosuvastatin HMGCR, PCSK9, PCSK7 CCNE1 3180/4885CDK2 1540/4885TACR1 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.